Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.

IF 4.2 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM American journal of physiology. Endocrinology and metabolism Pub Date : 2024-04-01 Epub Date: 2023-11-16 DOI:10.1152/ajpendo.00242.2023
Izabelle de Mello Gindri, Gustavo Ferrari, Luiz Paulo S Pinto, Juliana Bicca, Isis Kelly Dos Santos, Darlan Dallacosta, Carlos Rodrigo de Mello Roesler
{"title":"Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.","authors":"Izabelle de Mello Gindri, Gustavo Ferrari, Luiz Paulo S Pinto, Juliana Bicca, Isis Kelly Dos Santos, Darlan Dallacosta, Carlos Rodrigo de Mello Roesler","doi":"10.1152/ajpendo.00242.2023","DOIUrl":null,"url":null,"abstract":"<p><p>Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger and gene expression. The purpose of this systematic review is to examine whether the coenzyme formulae NAD<sup>+</sup> and NADH are safe and effective when acting as a supplement to humans. This systematic review of randomized clinical trials performed a search in six electronic databases: PubMed, MEDLINE (<i>ovid</i>), Embase, Cochrane CENTRAL (clinical trials), Web of Science, and Scopus. Secondary search included the databases (e.g., Clinical trials.gov, Rebec, Google Scholar - advance). Two reviewers assessed and extracted the studies independently. The risk of bias in studies was performed using version 2 of the Cochrane risk of bias tool for randomized trials. This review includes 10 studies, with a total of 489 participants. The studies included different clinical conditions, such as chronic fatigue syndrome (CFS), older adults, Parkinson's disease, overweight, postmenopausal prediabetes, and Alzheimer's disease. Based on studies, the supplementation with NADH and precursors was well tolerated and observed clinical results such as, a decrease in anxiety conditions and maximum heart rate was observed after a stress test, increased muscle insulin sensitivity, insulin signaling. Quality of life, fatigue intensity, and sleep quality among others were evaluated on patients with CFS. All studies showed some side effects, thus, the most common associated with NADs use are muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged by the studies did not present a serious risk to the health of the participants. Overall, these findings support that the oral administration of NADH can be associated to an increase in general quality of life and improvement on health parameters (e.g., a decrease in anxiety, maximum heart rate, inflammatory cytokines in serum, and cerebrospinal fluid). NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.</p>","PeriodicalId":7594,"journal":{"name":"American journal of physiology. Endocrinology and metabolism","volume":" ","pages":"E417-E427"},"PeriodicalIF":4.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of physiology. Endocrinology and metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1152/ajpendo.00242.2023","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide cofactor that is present in cells and in several important biological processes, including oxidative phosphorylation and production of adenosine triphosphate, DNA repair, calcium-dependent secondary messenger and gene expression. The purpose of this systematic review is to examine whether the coenzyme formulae NAD+ and NADH are safe and effective when acting as a supplement to humans. This systematic review of randomized clinical trials performed a search in six electronic databases: PubMed, MEDLINE (ovid), Embase, Cochrane CENTRAL (clinical trials), Web of Science, and Scopus. Secondary search included the databases (e.g., Clinical trials.gov, Rebec, Google Scholar - advance). Two reviewers assessed and extracted the studies independently. The risk of bias in studies was performed using version 2 of the Cochrane risk of bias tool for randomized trials. This review includes 10 studies, with a total of 489 participants. The studies included different clinical conditions, such as chronic fatigue syndrome (CFS), older adults, Parkinson's disease, overweight, postmenopausal prediabetes, and Alzheimer's disease. Based on studies, the supplementation with NADH and precursors was well tolerated and observed clinical results such as, a decrease in anxiety conditions and maximum heart rate was observed after a stress test, increased muscle insulin sensitivity, insulin signaling. Quality of life, fatigue intensity, and sleep quality among others were evaluated on patients with CFS. All studies showed some side effects, thus, the most common associated with NADs use are muscle pain, nervous disorders, fatigue, sleep disturbance, and headaches. All adverse events cataloged by the studies did not present a serious risk to the health of the participants. Overall, these findings support that the oral administration of NADH can be associated to an increase in general quality of life and improvement on health parameters (e.g., a decrease in anxiety, maximum heart rate, inflammatory cytokines in serum, and cerebrospinal fluid). NADH supplementation is safe and has a low incidence of side effects. Future investigations are needed to evidence the clinical benefits regarding specific diseases and doses administered.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评价NAD在不同临床条件下的安全性和有效性:一项系统综述。
目的:NAD+是一种必需的吡啶核苷酸辅助因子,存在于细胞中并参与几个重要的生物过程,包括氧化磷酸化和三磷酸腺苷的产生、DNA修复、钙依赖性次级信使和基因表达。本系统综述的目的是研究辅酶配方NAD+和NADH作为人体补充剂是否安全有效。方法:本系统综述对随机临床试验进行了6个电子数据库的检索。两名审稿人独立评估和提取研究。研究中的偏倚风险使用Cochrane随机试验偏倚风险工具的第2版进行。结果:本综述纳入10项研究,共纳入489名受试者。这些研究包括不同的临床状况,如慢性疲劳综合征(CFS);老年人;Parkison疾病;超重,绝经后前驱糖尿病和老年痴呆症根据研究,补充NADH和前体具有良好的耐受性,并观察到临床结果,例如,在压力测试后观察到焦虑状况和最大心率的减少,肌肉胰岛素敏感性和胰岛素信号的增加。对CFS患者的生活质量、疲劳强度、睡眠质量等进行评价。所有的研究都显示了一些副作用,因此,与NAD的使用最常见的相关是肌肉疼痛,神经紊乱,疲劳,睡眠障碍,头痛。研究中列出的所有不良事件都没有对参与者的健康构成严重风险。结论:总的来说,这些发现支持口服NADH可以提高总体生活质量和改善健康参数(例如,减少焦虑,最大心率)。补充NADH是安全的,副作用发生率低。需要进一步的研究来证明在特定疾病和给药剂量方面的临床益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
9.80
自引率
0.00%
发文量
98
审稿时长
1 months
期刊介绍: The American Journal of Physiology-Endocrinology and Metabolism publishes original, mechanistic studies on the physiology of endocrine and metabolic systems. Physiological, cellular, and molecular studies in whole animals or humans will be considered. Specific themes include, but are not limited to, mechanisms of hormone and growth factor action; hormonal and nutritional regulation of metabolism, inflammation, microbiome and energy balance; integrative organ cross talk; paracrine and autocrine control of endocrine cells; function and activation of hormone receptors; endocrine or metabolic control of channels, transporters, and membrane function; temporal analysis of hormone secretion and metabolism; and mathematical/kinetic modeling of metabolism. Novel molecular, immunological, or biophysical studies of hormone action are also welcome.
期刊最新文献
Metabolic effects of medium-chain triacylglycerol consumption are preserved in obesity. Early exposure to a cholinergic receptor blocking agent mitigates adult obesity and protects pancreatic islet function in male rats. Higher AMPK activation in mouse oxidative compared with glycolytic muscle does not correlate with LKB1 or CaMKKβ expression. Exploring CTRP6: a biomarker and therapeutic target in metabolic diseases. IGF-1 LR3 Does Not Promote Growth in Late Gestation Growth Restricted Fetal Sheep.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1